Cancer Molecular Genetics Prgm

癌症分子遗传学项目

• 批准号: 9365072
• 负责人: GORDON D GINDER
• 金额: $ 7.05万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9365072
• 关键词: Achievement; Behavior; Cancer Center; Cancer Center Support Grant; Cancerous; Cell Death; Cells; Cellular biology; Clinic; Collaborations; Defect; Dentistry; Development; Diagnosis; Epigenetic Process; Event; Funding; Funding Agency; Gene Expression; Genes; Genetic; Genetic Programming; Goals; Grant; Instruction; Knowledge; Laboratories; Malignant Neoplasms; Molecular; Molecular Genetics; Mutation; Normal Cell; Peer Review; Property; Public Health; Publications; Research; Research Personnel; Role; Signal Transduction; Therapeutic; United States National Institutes of Health; Universities; Virginia; base; cancer cell; cancer therapy; improved; innovation; interest; medical schools; member; multidisciplinary; next generation; programs; therapy development

The Cancer Molecular Genetics (CMG) program is a newly formed program resulting from the restructuring of the former Cancer Cell Biology program into two smaller and more cohesive programs [the other being the Cancer Cell Signaling (CCS) program]. Members of this program share a common interest in the genetic and epigenetic changes that underlie the molecular and cellular events contributing to cancer development and progression. The primary scientific goals of the CMG program are to define the genes contributing to cancer development and progression, to identify the genetic and epigenetic mechanisms regulating expression of these genes in normal and cancer cells, to determine their role in governing the properties and behaviors of cancer cells, to identify mechanisms by which identified defects in cancer cells can be exploited to selectively induce cancer cell death, and ultimately to use this knowledge to develop innovative approaches for the treatment of currently intractable cancers. The CMG program consists of a multidisciplinary group of 22 investigators from eight academic departments from the Schools of Medicine and Dentistry. The CMG program has a funding base of over $5.4 million dollars in annual direct support, of which more than $4.2 million is from NIH or other peer-reviewed funding sources. Members of the CMG program have multiple well-established and productive collaborations, both within the program and with members of other Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) programs, which have resulted in jointly funded research initiatives and high-impact publications in recent years. Greater than three-quarters of the 189 publications from CMG program members in the past grant period resulted from collaborations with other MCC members. 52% of which involved intra-programmatic, 48% involved inter-programmatic collaborations, and 2 1% involved both intra and inter- programmatic collaborations. The central goal of the CMG program is to facilitate achievement of the overarching goal of the MCC, namely to move laboratory advances into the clinic for improved diagnosis and therapy of cancer. By gaining a better understanding of the underlying molecular basis of cancer development and progression, it will be possible to develop the next generation of cancer therapeutics.

癌症分子遗传学(CMG)计划是重组后形成的一个新计划 将以前的癌细胞生物学计划分成两个更小、更有凝聚力的计划[另一个是 癌细胞信号(CCS)计划]。这项计划的成员在基因和 表观遗传学变化是导致癌症发生和发展的分子和细胞事件的基础 进步。CMG计划的主要科学目标是确定导致癌症的基因 发展和进展，以确定调控表达的遗传和表观遗传机制 这些基因在正常细胞和癌细胞中，以确定它们在调控 癌细胞，以确定可以选择性地利用癌细胞中已识别的缺陷的机制 诱导癌细胞死亡，并最终利用这一知识开发创新的方法 目前难以治愈的癌症的治疗。 CMG项目由来自8个学术部门的22名研究人员组成的多学科小组 从医学院和牙医学院毕业。CMG计划的资金基础超过540万美元 美元的年度直接支持，其中超过420万美元来自NIH或其他同行审查的资金 消息来源。CMG计划的成员拥有多种成熟和富有成效的合作关系，两者 在该计划内以及与弗吉尼亚联邦大学(VCU)梅西癌症的其他成员一起 中心(MCC)计划，这些计划产生了共同资助的研究倡议和高影响力 近几年的出版物。在CMG计划的189篇出版物中，超过四分之三 在过去的授权期内，成员是与其他MCC成员合作的结果。其中52% 涉及方案内，48%涉及方案间协作，21%同时涉及方案内和 方案间协作。 CMG计划的中心目标是促进实现MCC的总体目标，即 将实验室进展应用于临床，以改进癌症的诊断和治疗。通过获得更好的 了解癌症发生和发展的潜在分子基础，将有可能 开发下一代癌症疗法。